Objective and subjective outcome of clear lensectomy with toric IOL implantation after corneal collagen cross-linking in selected cases of keratoconus

Session Details

Session Title: Keratoconus & Secondary Ectasia

Session Date/Time: Sunday 15/09/2019 | 08:00-10:00

Paper Time: 08:00

Venue: Free Paper Forum: Podium 2

First Author: : W.Ali Abousamra EGYPT

Co Author(s): :    E. Azmy   A. Elkannishy                          

Abstract Details

Purpose:

To evaluate the visual and topographic outcomes of a two-stage approach treatment for selected cases of progressive keratoconus (KC); corneal collagen cross-linking (CXL) followed by phacoemulsification with toric intraocular lens (IOL) implantation.

Setting:

mansoura ophthalmic center, mansoura university

Methods:

The study included 9 eyes of 6 patients diagnosed with progressive KC, aged from 35 to 47 years (41.6±11.2 years). All studied eyes underwent a two-stage approach treatment: first corneal collagen CXL followed after at least 6 months by phacoemulsification with foldable toric IOL implantation in both eyes of three patients and only one eye of the other three patients. A complete ophthalmological examination was performed preoperatively and postoperatively. Topographical and visual outcomes were evaluated during 1-year follow-up period.

Results:

the sphere ranged from -3.00 to -8.00 D and cylinder from -3.50 to -5.50 D. All eyes should be corrected by glasses to 0.50 logMAR or more. 6 months after CXL, only Kmax decreased significantly, with no other significant changes. After toric IOL implantation, sphere changed from -5.74±1.88 to 0.33±0.72 D and cylinder changed from -4.53±0.98 to -1.10±0.76 D postoperatively. There was significant improvement in mean uncorrected distance visual acuity from logMAR 1.43±0.51 to 0.30±0.09 and the mean corrected distance visual acuity from 0.34±0.12 preoperatively to 0.24±0.13 one year after the procedure.

Conclusions:

This two-stage approach in selected cases of progressive KC is a safe and effective procedure regarding keratometric stability, and visual and refractive results.

Financial Disclosure:

None